Search

Search Constraints

You searched for: Author/Creator Reilly, Paul

Search Results

11. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. (August 2016)

12. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. (4th May 2017)

14. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Issue 6 (5th February 2019)

16. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Issue 10050 (17th September 2016)

17. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Issue 10050 (17th September 2016)

20. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. (18th June 2019)